Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 176,947,968
  • Shares Outstanding, K 4,465,000
  • Annual Sales, $ 46,792 M
  • Annual Income, $ 15,509 M
  • EBIT $ 19,327 M
  • EBITDA $ 22,656 M
  • 60-Month Beta 0.67
  • Price/Sales 4.52
  • Price/Cash Flow 10.12
  • Price/Book 7.21

Options Overview Details

View History
  • Implied Volatility 45.73% (-2.82%)
  • Historical Volatility 86.90%
  • IV Percentile 45%
  • IV Rank 28.86%
  • IV High 70.99% on 04/08/25
  • IV Low 35.49% on 12/31/25
  • Expected Move (DTE 3) 1.10 (2.84%)
  • Put/Call Vol Ratio 0.80
  • Today's Volume 164,567
  • Volume Avg (30-Day) 118,662
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 1,430,207
  • Open Int (30-Day) 1,456,061
  • Expected Range 37.49 to 39.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.88
  • Number of Estimates 5
  • High Estimate 0.99
  • Low Estimate 0.78
  • Prior Year 0.92
  • Growth Rate Est. (year over year) -4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.36 +0.60%
on 02/24/26
63.99 -39.70%
on 01/26/26
-23.67 (-38.02%)
since 01/23/26
3-Month
38.36 +0.60%
on 02/24/26
64.16 -39.85%
on 01/23/26
-6.38 (-14.19%)
since 11/24/25
52-Week
38.36 +0.60%
on 02/24/26
93.80 -58.86%
on 02/25/25
-52.00 (-57.40%)
since 02/24/25

Most Recent Stories

More News
Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

NVO : 38.59 (-2.62%)
LLY : 1,042.15 (-1.55%)
Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO

The DJS Law Group announces that it is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or “the Company”) (NYSE: NVO ) for violations of the...

NVO : 38.59 (-2.62%)
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or “the Company”)...

NVO : 38.59 (-2.62%)
Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

HIMS is down 48% in the past month following a Novo Nordisk lawsuit. But, analysts expect record revenue when the company reports earnings this month.

HIMS : 15.46 (-0.32%)
NVO : 38.59 (-2.62%)
As Hims & Hers Gets Hit With Major Wegovy Loss, Should You Buy the Dip in Deeply Oversold HIMS Stock?

Hims & Hers shares crater as Novo Nordisk files a lawsuit against the telehealth firm. BofA analysts see significant further downside in HIMS stock.

HIMS : 15.46 (-0.32%)
NVO : 38.59 (-2.62%)
Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

HIMS : 15.46 (-0.32%)
NVO : 38.59 (-2.62%)
JNJ : 246.28 (+0.18%)
LLY : 1,042.15 (-1.55%)
Unusual Options Activity Alert: 3 Stocks Setting Up for Major Profit Potential

Volatility returned to markets yesterday, triggering a tech rout. Among the unusually active options on Thursday were 278 calls and puts with Vol/OI ratios of 15 or higher. Among them, these 3 stocks offer...

MSTR : 124.61 (+0.73%)
VFC : 19.77 (+0.46%)
QCOM : 144.78 (+3.11%)
ETSY : 54.40 (+3.88%)
LOGI : 91.36 (+2.22%)
NVO : 38.59 (-2.62%)
LLY : 1,042.15 (-1.55%)
PFE : 27.14 (+0.30%)
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.

NVO : 38.59 (-2.62%)
LLY : 1,042.15 (-1.55%)
As Novo Nordisk Stock Breaks Below Key Support Levels, Should You Buy the Dip?

Novo Nordisk stock sank as management forecasts decelerating growth in 2026. But should you treat this selloff in NVO shares as a buying opportunity? Let’s find out.

NVO : 38.59 (-2.62%)
LLY : 1,042.15 (-1.55%)
Commodity Volatility, Earnings and Other Key Things to Watch

Markets enter February following a volatile final trading day of January that saw investors grappling with hotter-than-expected inflation data alongside news of a new Federal Reserve chair nominee.

PYPL : 47.02 (+6.74%)
MSTR : 124.61 (+0.73%)
GOOGL : 310.90 (-0.19%)
NVO : 38.59 (-2.62%)
MRK : 123.93 (+0.09%)
PFE : 27.14 (+0.30%)
DIS : 106.05 (+1.57%)
QCOM : 144.78 (+3.11%)
LLY : 1,042.15 (-1.55%)
AMD : 213.84 (+8.77%)
RBLX : 67.09 (+7.46%)
ARM : 128.14 (+3.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 39.70
2nd Resistance Point 39.38
1st Resistance Point 38.99
Last Price 38.59
1st Support Level 38.28
2nd Support Level 37.96
3rd Support Level 37.57

See More

52-Week High 93.80
Fibonacci 61.8% 72.62
Fibonacci 50% 66.08
Fibonacci 38.2% 59.54
Last Price 38.59
52-Week Low 38.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar